Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Dynavax Technologies (DVAX)

Dynavax Technologies (DVAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Dynavax Technologies 2100 Powell Street Suite 720 Emeryville CA 94608 USA

www.dynavax.com P: 510-848-5100 F: 510-848-1327

Description:

Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.

Key Statistics

Overview:

Market Capitalization, $K 1,495,764
Enterprise Value, $K 1,375,204
Shares Outstanding, K 130,863
Annual Sales, $ 232,280 K
Annual Net Income, $ -6,390 K
Last Quarter Sales, $ 55,600 K
Last Quarter Net Income, $ 220 K
EBIT, $ -37,020 K
EBITDA, $ -46,300 K
60-Month Beta 1.26
% of Insider Shareholders 2.62%
% of Institutional Shareholders 96.96%
Float, K 127,434
% Float 97.38%
Short Volume Ratio 0.57

Growth:

1-Year Return 2.72%
3-Year Return 18.25%
5-Year Return 66.76%
5-Year Revenue Growth 2,732.68%
5-Year Earnings Growth 98.04%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.00 on 02/22/24
Latest Earnings Date 05/07/24
Earnings Per Share ttm -0.06
EPS Growth vs. Prev Qtr -100.00%
EPS Growth vs. Prev Year -100.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 11/10/14

DVAX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward 49.39
Price/Earnings to Growth N/A
Return-on-Equity % -1.08%
Return-on-Assets % -0.66%
Profit Margin % -2.75%
Debt/Equity 0.05
Price/Sales 6.47
Price/Cash Flow N/A
Price/Book 2.43
Book Value/Share 4.81
Interest Coverage -0.35
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar